Development of a THP-1 Assay Ready Product for Cell-Based Assays
Discovery on Target 2024
Boston, Massachusetts, United States
October 02, 2024Abstract
Cell-based assays are extensively used in both research and industry settings for a wide variety of applications including target identification, drug development, and compound toxicity testing. A major challenge when using cell-based assays is the inherent variability of cultured cells. The parameters that contribute to this variability include cell culture practice, phenotypic drift associated with long-term cell cultivation, and biomaterials resourced from different labs. The disadvantages of maintaining continuous culture have driven the need for cell products that are ready for immediate use in cell-based assays.
Here, we report the development of ATCC TIB-202-AR, a standardized assay-ready cell (ARC) product utilizing the ATCC TIB-202 THP-1 cell line—a commonly used and physiologically relevant cell model that is known to be difficult to handle. During product development and manufacturing, high standards and strict cell culture processes were used for maintaining the characteristics and authenticity of the culture, and a proprietary animal by-product (ABP)-free cryomedium was developed to freeze the cells.
ATCC TIB-202-AR was manufactured to meet the defined specifications for low intra-lot and inter-lot variation and demonstrates repeatability in achieving optimal performance in cell-based assays. It consistently exhibits high viability, fast recovery post-thaw, and the ability to differentiate into macrophage-like cells that express the appropriate macrophage markers and display the expected functional attributes. Our THP-1 ARC product offers improvements in use of laboratory resources, experiment scheduling, and assay robustness and variability, allowing for extensive study of biopharmaceuticals while avoiding the lengthy and costly development normally required for establishing cell-based assays.
Download the poster to learn about our ThawReady™ cells
DownloadPresenter
Diana Douglas, BS
Lead Biologist, ATCC
Diana Douglas is a Lead Biologist at ATCC. For the last nine years, she has focused her research on the development of advanced biological models including the use of CRISPR/Cas9 gene-editing technology. Previously, Ms. Douglas worked at the Baker Institute for Animal Health at Cornell University and the Dalton Cardiovascular Research Center at the University of Missouri, where her research focused on the mechanisms of necrotic cell death in heart disease. Ms. Douglas attended Truman State University where she obtained a Bachelor of Science in Biology.
Cell-based assays have lengthy timelines due to the requirement of cell expansion processes to get a synchronized cell stock. To speed your timelines while providing you with the consistency you need, ATCC developed ThawReady™ Assay Ready Cells. ATCC ThawReady™ products will streamline your workflows by months, allowing you to focus on advancing drug discovery and development. You simply thaw, plate, and go.
Explore now